Compare Stocks

→ Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNO United States Brent Oil Fund	$32.72 +0.1%	$31.43	$24.02 ▼ $33.91	$132.52M	0.2	592,936 shs	380,572 shs
EMH Emerald Health Therapeutics	C$0.26 -3.8%	C$0.26	C$0.15 ▼ C$0.53	C$52.28M	N/A	644,760 shs	384,329 shs
PMN ProMIS Neurosciences	$1.98 +1.5%	$2.04	$0.95 ▼ $8.95	$37.54M	0.67	37,766 shs	1,032 shs
RZLT Rezolute	$2.66 +2.3%	$2.22	$0.72 ▼ $3.69	$106.75M	1.29	312,882 shs	202,569 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNO United States Brent Oil Fund	+0.99%	+2.00%	+4.18%	+9.66%	+25.35%
EMH Emerald Health Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
PMN ProMIS Neurosciences	0.00%	-1.02%	+0.52%	-3.05%	-71.28%
RZLT Rezolute	-10.03%	-21.21%	+22.64%	+136.36%	+30.00%

Protect Yourself While There’s Still Time … (Ad)

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNO United States Brent Oil Fund	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EMH Emerald Health Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PMN ProMIS Neurosciences	2.9841 of 5 stars	3.5	4.0	0.0	0.0	3.2	1.7	0.6
RZLT Rezolute	3.574 of 5 stars	3.5	4.0	0.0	0.0	3.0	4.2	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNO United States Brent Oil Fund	0.00	N/A	N/A	N/A
EMH Emerald Health Therapeutics	N/A	N/A	N/A	N/A
PMN ProMIS Neurosciences	3.00	Buy	$8.00	304.04% Upside
RZLT Rezolute	3.00	Buy	$8.80	230.83% Upside

Current Analyst Ratings

Latest PMN, RZLT, EMH, ZLD, and BNO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/18/2024	RZLT Rezolute	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$7.00
4/18/2024	RZLT Rezolute	Jonestrading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
4/9/2024	RZLT Rezolute	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
3/7/2024	RZLT Rezolute	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
2/14/2024	RZLT Rezolute	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNO United States Brent Oil Fund	N/A	N/A	N/A	N/A	N/A	N/A
EMH Emerald Health Therapeutics	C$13.02M	4.02	C$0.33 per share	0.78	C$0.40 per share	0.64
PMN ProMIS Neurosciences	$10K	3,754.08	N/A	N/A	$0.20 per share	9.90
RZLT Rezolute	N/A	N/A	N/A	N/A	$3.15 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNO United States Brent Oil Fund	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
EMH Emerald Health Therapeutics	N/A	-C$0.70	N/A	∞	N/A	N/A	N/A	N/A	N/A
PMN ProMIS Neurosciences	-$13.21M	-$1.13	N/A	N/A	N/A	N/A	N/A	-141.23%	5/20/2024 (Estimated)
RZLT Rezolute	-$51.79M	-$1.10	N/A	N/A	N/A	N/A	-51.81%	-48.05%	5/9/2024 (Estimated)

Latest PMN, RZLT, EMH, ZLD, and BNO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
4/1/2024	Q4 2023	PMN ProMIS Neurosciences	N/A	-$0.09	-$0.09	-$0.09	N/A	N/A
2/13/2024	Q2 2024	RZLT Rezolute	-$0.27	-$0.27	N/A	-$0.27	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNO United States Brent Oil Fund	N/A	N/A	N/A	N/A	N/A
EMH Emerald Health Therapeutics	N/A	N/A	N/A	N/A	N/A
PMN ProMIS Neurosciences	N/A	N/A	N/A	N/A	N/A
RZLT Rezolute	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNO United States Brent Oil Fund	N/A	N/A	N/A
EMH Emerald Health Therapeutics	35.45	2.97	2.61
PMN ProMIS Neurosciences	N/A	1.46	1.46
RZLT Rezolute	N/A	12.00	12.00

Ownership

Institutional Ownership

Company	Institutional Ownership
BNO United States Brent Oil Fund	N/A
EMH Emerald Health Therapeutics	N/A
PMN ProMIS Neurosciences	50.13%
RZLT Rezolute	82.97%

Insider Ownership

Company	Insider Ownership
BNO United States Brent Oil Fund	N/A
EMH Emerald Health Therapeutics	N/A
PMN ProMIS Neurosciences	10.30%
RZLT Rezolute	18.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BNO United States Brent Oil Fund	N/A	4.05 million	N/A	Not Optionable
EMH Emerald Health Therapeutics	161	205.03 million	N/A	Not Optionable
PMN ProMIS Neurosciences	6	18.96 million	17.01 million	Not Optionable
RZLT Rezolute	57	40.13 million	32.83 million	Not Optionable

PMN, RZLT, EMH, ZLD, and BNO Headlines

Source	Headline
	Federated Hermes Inc. Purchases 3,544,053 Shares of Rezolute, Inc. (NASDAQ:RZLT) marketbeat.com - April 24 at 5:43 AM
	Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting globenewswire.com - April 23 at 8:00 AM
	Rezolute (NASDAQ:RZLT) Now Covered by Jonestrading americanbankingnews.com - April 20 at 4:42 AM
	Rezolute (NASDAQ:RZLT) Stock Rating Reaffirmed by JMP Securities americanbankingnews.com - April 20 at 1:54 AM
	JonesTrading Initiates Coverage of Rezolute (RZLT) with Buy Recommendation msn.com - April 19 at 8:15 AM
	Rezolute (NASDAQ:RZLT) Given Market Outperform Rating at JMP Securities marketbeat.com - April 18 at 2:21 PM
	Jonestrading Begins Coverage on Rezolute (NASDAQ:RZLT) marketbeat.com - April 18 at 8:35 AM
	Optimistic Buy Rating for Rezolute’s RZ402 Drug Candidate Amid Promising DME Treatment Prospects markets.businessinsider.com - April 18 at 5:30 AM
	Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024? investorplace.com - April 15 at 3:43 PM
	Rezolute Stock (NASDAQ:RZLT), Analyst Ratings, Price Targets, Predictions benzinga.com - April 10 at 4:10 PM
	Rezolute (NASDAQ:RZLT) Earns Buy Rating from Analysts at Maxim Group marketbeat.com - April 9 at 8:23 AM
	Insiders Are Buying These 5 Penny Stocks insidermonkey.com - April 4 at 8:51 AM
	Rezolute, Inc. (NASDAQ:RZLT) Short Interest Update marketbeat.com - March 27 at 9:30 PM
	Rezolute Reaches US$75m Market Cap Benefiting Insider Stock Buying finance.yahoo.com - March 27 at 8:51 AM
	3 Stocks Insiders Are Buying That Analysts Love (RZLT) insidertrades.com - March 26 at 12:55 PM
	Rezolute's chief medical officer buys $18.8k in company stock investing.com - March 20 at 5:29 PM
	Daron Evans Buys 20,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock insidertrades.com - March 20 at 7:32 AM
	Brian Kenneth Roberts Acquires 10,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock insidertrades.com - March 19 at 5:40 AM
	Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) Director Buys 36,503 Shares of Stock insidertrades.com - March 15 at 11:42 AM
	Rezolute, Inc. (NASDAQ:RZLT) CFO Acquires $96,500.00 in Stock insidertrades.com - March 11 at 7:22 AM
	Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH) globenewswire.com - March 6 at 7:30 AM
	Rezolute Stock (NASDAQ:RZLT) Earnings Dates and Earning Calls benzinga.com - February 22 at 12:13 PM
	Rezolute, Inc.: Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update finanznachrichten.de - February 16 at 9:03 AM
	We're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate finance.yahoo.com - February 15 at 7:59 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

United States Brent Oil Fund

NYSEARCA:BNO

The United States Brent Oil Fund, LP (BNO) is an exchange-traded fund that is based on the Front Month Brent Crude Oil index. The fund tracks the Brent oil spot price using near-month ICE futures contracts. BNO was launched on Jun 2, 2010 and is managed by US Commodity Funds.

Emerald Health Therapeutics

CVE:EMH

Emerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis for medical purpose in Canada. The company is also involved in developing natural health products. It offers dried cannabis strains, pre-rolls, and cannabis oil products to its medical patients. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.

ProMIS Neurosciences

NASDAQ:PMN

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Rezolute

NASDAQ:RZLT

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial